Abstract Number: 1710 • ACR Convergence 2022
CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by overproduction of type I interferons (IFNs) and sensitivity to ultraviolet (UV) light. Though…Abstract Number: 0208 • ACR Convergence 2022
Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)
Background/Purpose: Retrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in DM, as measured by CDASI-A.…Abstract Number: 1766 • ACR Convergence 2022
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…Abstract Number: 0211 • ACR Convergence 2022
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they…Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…Abstract Number: 0318 • ACR Convergence 2022
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods…Abstract Number: 1862 • ACR Convergence 2022
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…Abstract Number: 0335 • ACR Convergence 2022
Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are both characterized histologically by interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate, requiring clinical correlation…Abstract Number: 2267 • ACR Convergence 2022
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
Background/Purpose: Type 1 interferons (IFN-1) are major drivers of disease activity in systemic (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs) are the…Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…Abstract Number: 0364 • ACR Convergence 2022
Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)
Background/Purpose: SLE is a heterogeneous illness that often manifests with skin and/or joint diseases.1 BIIB059 is a humanized monoclonal antibody that binds to BDCA2, a…Abstract Number: 0365 • ACR Convergence 2022
Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)
Background/Purpose: BIIB059 is a humanized monoclonal antibody against BDCA2, a receptor exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of cutaneous…Abstract Number: 0556 • ACR Convergence 2022
Immune Checkpoint VISTA Regulates Type I Interferon (IFN-I) Production and Controls UV Light Triggered Skin IFN-I Response
Background/Purpose: Most lupus patients chronically exhibit higher IFN-I scores in the skin, peripheral blood, and kidneys that is exacerbated by ultraviolet (UV) light. In normal…Abstract Number: 0661 • ACR Convergence 2022
Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogenous, disfiguring, and difficult-to-treat manifestation of systemic lupus erythematosus (SLE) with scar formation in CLE subtypes such as…Abstract Number: 0974 • ACR Convergence 2022
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype…
ACR Meeting Abstracts